



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Simons et al.  
Serial No. : 09/145,916  
Filed For : September 2, 1998  
"STIMULATION OF ANGIOGENESIS VIA  
ENHANCED ENDOTHELIAL EXPRESSION  
OF SYNDECAN-4 CORE PROTEINS"  
Examiner : David Guzo  
Group Art Unit : 1636  
Attorney's Docket No. : BIS-039

\*\*\*\*\*

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to Assistant Commissioner for Patents, Washington, D.C. 20231

on: July 19, 2001.

Attorney for Applicants: David Prashker

Signature: David Prashker

Date: July 19, 2001

\*\*\*\*\*

REPLY TO NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT  
APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR  
AMINO ACID SEQUENCE DISCLOSURES

Assistant Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

In response to the Notice To Comply With Requirements For  
Patent Applications Containing Nucleotide Sequence And/Or Amino  
Acid Sequence Disclosures mailed April 2, 2001, as extended through  
August 2, 2001, please find enclosed the following documents for filing

TECH CENTER 1600/2900

JUL 3 0 2001

RECEIVED

on behalf of applicants and for formal entry into the above-identified application:

1. A third paper form copy of the "Sequence Listing" to be formally entered into the original Specification of the above-identified patent application.
2. A Third Amendment Of Specification And Request For Entry Of A Paper Form Copy Of The Sequence Listing Containing Nucleotide Sequence And/or Amino Acid Sequence Disclosures.
3. A third computer readable form (CRF) copy of the "Sequence Listing".
4. A Third Statement And Verification Of Substantive Identity Between The Computer Readable Form (CRF) Copy And The Paper Form Copy Of The "Sequence Listing".
5. One copy of the Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures as mailed April 2, 2001.


Respectfully submitted,

SIMONS *et al.*

By:   
David Prashker  
Reg. No. 29,693  
Attorney for applicants

Date: July 19, 2001  
P.O. Box 5387  
Magnolia, Massachusetts 01930  
Tel.: (978) 525-3794

JUL 24 2001



*Applicant's Copy*

Application No.

09/145916

TECH CENTER 1600/2900

JUL 30 2001

RECEIVED

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821 - 1.825 for the following reason(s):

1. This application clearly fails to comply with the requirements of 37 CFR 1.821 - 1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.

2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 CFR 1.821(c).

3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e).

4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 CFR 1.822 and/or 1.823, as indicated on the attached copy of the marked-up "Raw Sequence Listing."

5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 CFR 1.825(d).

6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 CFR 1.821(e).

7.

Other: \_\_\_\_\_

Applicant must provide:

An initial or substitute computer readable form (CRF) copy of the "Sequence Listing"

An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification

A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 CFR 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d)

For questions regarding compliance with these requirements, please contact:

For Rules Interpretation, call (703) 308-1123

For CRF submission help, call (703) 308-4212

For PatentIn software help, call (703) 557-0400